Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01041781 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Terminated
- Registry status
- Phase 3
- Development phase
- 313
- Enrollment target
NCT01041781 is a Phase 3 study that was terminated before completion, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 313 participants.
The verdict
NCT01041781, a Phase 3 study, was terminated before completion, sponsored by Alliance for Clinical Trials in Oncology.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 313 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving gemcitabine hydrochloride or pemetrexed disodium together with carboplatin is more effective with or without celecoxib in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying gemcitabine hydrochloride, pemetrexed disodium, and carboplatin to compare how well they work when given together with celecoxib or a placebo in treating patients with advanced non-small cell lung cancer.
Interventions
- OTHER placebo
- DRUG carboplatin
- DRUG gemcitabine hydrochloride
- DRUG pemetrexed disodium
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2010-02 |
| Est. Completion | 2018-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01041781
The ClinicalTrials.gov registry entry for NCT01041781 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT01041781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01041781 about?
NCT01041781 is a clinical study titled "Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium and celecoxib may stop the growth of tumor cells by blocking some of ...
What is the current status of trial NCT01041781?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 313 participants. The study started on 2010-02. Estimated completion is 2018-03.
What interventions are being tested in trial NCT01041781?
The interventions under investigation include: placebo (OTHER), carboplatin (DRUG), gemcitabine hydrochloride (DRUG), pemetrexed disodium (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT01041781?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.